About Us
SinoMab BioScience Limited (“SinoMab” or the “Company”, stock code: 3681.HK) is dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases. The Company’s flagship product SM03 is a potential global first-in-target mAb against CD22 for the treatment of rheumatoid arthritis and is currently in Phase III clinical trial for rheumatoid arthritis in China, which has been recognized as one of the significant special projects of Significant New Drugs Development of the Thirteenth Five-Year Plan Period.

Product Pipeline


Core Product
Anti-CD22
First-in-Target


NCE
Drug Candidate
BTK Inhibitor
Third-Generation


Biologic Candidates
Humanized Anti-IL17BR
First-in-Class and First-in-Target


Humanized Anti-CD20


Humanized Anti-CD22
What's News
Our Office
- Units 303 and 305 to 307,
No.15 Science Park West Avenue,
Hong Kong Science Park, Pak Shek Kok,
New Territories, Hong Kong
